Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027

Vaxart, Inc.

Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.
Revenue $237.3M, up from $28.7M, driven by BARDA contract and Dynavax collaboration.
Cash, equivalents & investments $63.8M; runway into Q2 2027.
COVID-19 Phase 2b sentinel cohort data (400 subjects) expected early Q2 2026; main cohort topline Q4 2026.
Published Phase 1 norovirus data shows passive antibody transfer to infants via breast milk; next trial dependent on partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.